RAHWAY, N.J., June 05, 2024--Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Monday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study. The study is evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Merck’s Keytruda in patients with resected high-risk melanoma (stage III/IV) following complete resection (n=157). With a median follow-up of approximately three years (34.9 months), adjuvant tr
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...